vs
Side-by-side financial comparison of First Seacoast Bancorp, Inc. (FSEA) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.
Taysha Gene Therapies, Inc. is the larger business by last-quarter revenue ($5.5M vs $4.0M, roughly 1.4× First Seacoast Bancorp, Inc.). First Seacoast Bancorp, Inc. runs the higher net margin — -2.4% vs -507.8%, a 505.4% gap on every dollar of revenue. On growth, Taysha Gene Therapies, Inc. posted the faster year-over-year revenue change (171.3% vs 20.6%). Over the past eight quarters, Taysha Gene Therapies, Inc.'s revenue compounded faster (26.8% CAGR vs 12.6%).
Sterling Bancorp was an American regional bank holding company that owned Sterling National Bank. It merged into Webster Bank in February 2022.
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
FSEA vs TSHA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.0M | $5.5M |
| Net Profit | $-87.0K | $-27.9M |
| Gross Margin | — | — |
| Operating Margin | -3.1% | -516.0% |
| Net Margin | -2.4% | -507.8% |
| Revenue YoY | 20.6% | 171.3% |
| Net Profit YoY | 93.8% | -48.3% |
| EPS (diluted) | $-0.04 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.0M | $5.5M | ||
| Q3 25 | $4.0M | $0 | ||
| Q2 25 | $3.9M | $2.0M | ||
| Q1 25 | $3.5M | $2.3M | ||
| Q4 24 | $3.4M | $2.0M | ||
| Q3 24 | $3.3M | $1.8M | ||
| Q2 24 | $5.9M | $1.1M | ||
| Q1 24 | $3.2M | $3.4M |
| Q4 25 | $-87.0K | $-27.9M | ||
| Q3 25 | $390.0K | $-32.7M | ||
| Q2 25 | $-545.0K | $-26.9M | ||
| Q1 25 | $-603.0K | $-21.5M | ||
| Q4 24 | $-1.4M | $-18.8M | ||
| Q3 24 | $44.0K | $-25.5M | ||
| Q2 24 | $2.0M | $-20.9M | ||
| Q1 24 | $-1.2M | $-24.1M |
| Q4 25 | -3.1% | -516.0% | ||
| Q3 25 | -5.2% | — | ||
| Q2 25 | -13.7% | -1347.1% | ||
| Q1 25 | -17.9% | -930.5% | ||
| Q4 24 | -23.5% | -985.8% | ||
| Q3 24 | -17.8% | -1448.4% | ||
| Q2 24 | 35.6% | -1915.4% | ||
| Q1 24 | -24.8% | -713.3% |
| Q4 25 | -2.4% | -507.8% | ||
| Q3 25 | 9.8% | — | ||
| Q2 25 | -14.1% | -1353.6% | ||
| Q1 25 | -17.1% | -935.2% | ||
| Q4 24 | -46.9% | -929.0% | ||
| Q3 24 | 1.3% | -1427.5% | ||
| Q2 24 | 33.9% | -1882.0% | ||
| Q1 24 | -36.1% | -705.4% |
| Q4 25 | $-0.04 | $-0.08 | ||
| Q3 25 | $0.08 | $-0.09 | ||
| Q2 25 | $-0.13 | $-0.09 | ||
| Q1 25 | $-0.14 | $-0.08 | ||
| Q4 24 | $-0.31 | $-0.07 | ||
| Q3 24 | $0.01 | $-0.10 | ||
| Q2 24 | $0.42 | $-0.09 | ||
| Q1 24 | $-0.24 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $319.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $63.5M | $246.9M |
| Total Assets | $599.3M | $343.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $319.8M | ||
| Q3 25 | — | $297.3M | ||
| Q2 25 | — | $312.8M | ||
| Q1 25 | — | $116.6M | ||
| Q4 24 | — | $139.0M | ||
| Q3 24 | — | $157.7M | ||
| Q2 24 | — | $172.7M | ||
| Q1 24 | — | $124.0M |
| Q4 25 | $63.5M | $246.9M | ||
| Q3 25 | $63.2M | $219.0M | ||
| Q2 25 | $60.8M | $248.7M | ||
| Q1 25 | $61.2M | $55.1M | ||
| Q4 24 | $62.0M | $71.5M | ||
| Q3 24 | $65.8M | $88.8M | ||
| Q2 24 | $64.5M | $108.9M | ||
| Q1 24 | $64.7M | $53.8M |
| Q4 25 | $599.3M | $343.3M | ||
| Q3 25 | $609.6M | $316.6M | ||
| Q2 25 | $604.8M | $333.3M | ||
| Q1 25 | $592.6M | $138.4M | ||
| Q4 24 | $580.8M | $160.4M | ||
| Q3 24 | $601.8M | $180.2M | ||
| Q2 24 | $601.7M | $200.4M | ||
| Q1 24 | $576.5M | $153.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $449.0K | $-26.7M |
| Free Cash FlowOCF − Capex | $329.0K | — |
| FCF MarginFCF / Revenue | 8.1% | — |
| Capex IntensityCapex / Revenue | 3.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $449.0K | $-26.7M | ||
| Q3 25 | $661.0K | $-24.2M | ||
| Q2 25 | $-151.0K | $-20.2M | ||
| Q1 25 | $573.0K | $-22.0M | ||
| Q4 24 | $-2.9M | $-18.3M | ||
| Q3 24 | $289.0K | $-21.6M | ||
| Q2 24 | $-1.4M | $-21.5M | ||
| Q1 24 | $-70.0K | $-19.8M |
| Q4 25 | $329.0K | — | ||
| Q3 25 | $640.0K | $-24.3M | ||
| Q2 25 | $-154.0K | — | ||
| Q1 25 | $542.0K | — | ||
| Q4 24 | $-3.3M | $-18.3M | ||
| Q3 24 | $264.0K | $-21.6M | ||
| Q2 24 | $-1.6M | $-21.7M | ||
| Q1 24 | $-81.0K | $-19.9M |
| Q4 25 | 8.1% | — | ||
| Q3 25 | 16.0% | — | ||
| Q2 25 | -4.0% | — | ||
| Q1 25 | 15.4% | — | ||
| Q4 24 | -99.0% | -905.5% | ||
| Q3 24 | 7.9% | -1210.9% | ||
| Q2 24 | -26.5% | -1951.9% | ||
| Q1 24 | -2.5% | -584.5% |
| Q4 25 | 3.0% | — | ||
| Q3 25 | 0.5% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.9% | — | ||
| Q4 24 | 11.0% | 0.1% | ||
| Q3 24 | 0.7% | 2.0% | ||
| Q2 24 | 2.8% | 18.1% | ||
| Q1 24 | 0.3% | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | 1.69× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 6.57× | — | ||
| Q2 24 | -0.70× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
